Neurocysticercosis in children.
Twenty seven cases (13 male, 14 female) in the age group of 3-12 years with cerebral cysticercosis were studied and followed up to 3.9 years (mean 1.85 +/- 0.91 years). Seizures (partial 76% and generalized 23.8%) was the feature in 21 patients (77.7%) and raised intracranial tension in 15 (55.5%). Five patients (18.2%) had meningoencephalitis, while 4 (14.8%) had obstructive hydrocephalus due to intraventricular cysts in the 4th ventricle. Twenty two patients received cysticidal drugs (praziquantel or albendazole), while 8 had surgical intervention (CSF diversion, cyst removal, subtemporal decompression or extirpation of the cortical cyst). Mortality was 18.2%. Survivors had epilepsy in 18 patients (81.8%), dementia in 2 (9%), mental subnormality in 6 (27.2%) and hyperkinesia in 12 (54.5%).
Puri
V
V
Department of Neurology, G.B. Pant Hospital, New Delhi.
Sharma
D K
DK
Kumar
S
S
Choudhury
V
V
Gupta
R K
RK
Khalil
A
A
D000293:Adolescent; D015766:Albendazole / Q000627:therapeutic use; D001927:Brain Diseases / Q000175:diagnosis / Q000628:therapy; D002648:Child; D002675:Child, Preschool; D003551:Cysticercosis / Q000150:complications / Q000628:therapy; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000209:etiology; D005260:Female; D006801:Humans; D006849:Hydrocephalus / Q000209:etiology; D007427:Intracranial Pressure; D008297:Male; D008590:Meningoencephalitis / Q000209:etiology; D011223:Praziquantel / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed
D011223:Praziquantel; D015766:Albendazole